|OxThera AB Receives SEK 70 Million Financing to Continue its Key Clinical ...|
OxThera is currently conducting a phase 2 clinical study to demonstrate the clinical efficacy of Oxabact®, in Primary Hyperoxaluria (PH). "OxThera is the first investment for Kurma Biofund II, our new fund dedicated to rare diseases, and we are very ...
PR Newswire (press release) - Wed, 16 Apr 2014 01:01
|Here are the Mass. biotechs that lost the most value in the recent sell-off|
The Watertown biotech is developing RNA-interference drugs, with its lead drug potentially aimed at an inherited kidney disease called primary hyperoxaluria. Synta Pharmaceuticals (Nasdaq: SNTA): down 41 percent. The Lexington firm was founded in 2001 ...
Boston Business Journal (blog) - Wed, 09 Apr 2014 10:42
|Jefferies Biotech Stocks to Buy With Breakthrough Drug Innovations|
Dicerna has selected its first liver-targeted clinical candidate, primary hyperoxaluria, and expects to enter the clinic by early 2015, with data in its first indication by mid-2015. The company is another Buy-rated stock at Jefferies, and its price ...
24/7 Wall St. - Thu, 03 Apr 2014 05:30
|Dicerna Announces Fourth Quarter and Full Year 2013 Financial and ...|
DCR-PH1 is a therapeutic candidate for Primary Hyperoxaluria (PH1), a rare, inherited autosomal recessive disorder of metabolism in the liver that usually results in severe damage to the kidneys. Developed using DsiRNA and EnCore lipid nanoparticle ...
Business Wire (press release) - Thu, 27 Mar 2014 12:52
|Dicerna Pharmaceuticals Inc.: Dicerna Announces Fourth Quarter and Full Year ...|
The Wall Street Transcript - Thu, 27 Mar 2014 13:51
|Texas Children's Hospital performs more solid organ transplants than any other ...|
... is staffed by transplant surgeons, pediatric urologists and pediatric nephrologists with expertise in the breadth of pediatric kidney diseases ranging from chronic glomerulonephritis to rare hereditary diseases, such as primary hyperoxaluria and ...
Insurance News Net (press release) - Tue, 25 Mar 2014 09:30